

Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn19>

Nucleoside Analogues of Purine with a 1,2-Disubstituted Cyclopentene Ring

P. Besada^a, C. Terán^a, L. Santana^b, M. Teijeira^b & E. Uriarte^b

^a Departamento de Química Física y Química Orgánica, Universidad de Vigo, Spain

^b Facultad de Farmacia, Universidad de Santiago de Compostela, Spain

Published online: 04 Oct 2006.

To cite this article: P. Besada, C. Terán, L. Santana, M. Teijeira & E. Uriarte (1999) Nucleoside Analogues of Purine with a 1,2-Disubstituted Cyclopentene Ring, *Nucleosides and Nucleotides*, 18:4-5, 725-726, DOI: [10.1080/15257779908041554](https://doi.org/10.1080/15257779908041554)

To link to this article: <http://dx.doi.org/10.1080/15257779908041554>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

NUCLEOSIDE ANALOGUES OF PURINE WITH A 1,2-DISUBSTITUTED CYCLOPENTENE RING

P. Besada^a, C. Terán^{a*}, L. Santana^b, M. Teijeira^b and E. Uriarte^b

^a*Departamento de Química Física y Química Orgánica, Universidad de Vigo, Spain*

^b*Facultad de Farmacia, Universidad de Santiago de Compostela, Spain*


ABSTRACT. One, two-disubstituted carbonucleoside analogues of purine with unsaturated carbocyclic were synthesized by construction of the heterocyclic base about the primary amino group of the amino alcohol **4** intermediate, which was also synthesized in good yield starting from cyclopentadiene.

Following our previous work on carbocyclic nucleoside analogues one, two-disubstituted carbonucleosides (OTCs-cyclopentanes with a hydroxymethyl group and the heterocyclic base attached to contiguous ring carbons), we describe here the preparation of compounds with an unsaturation in the 2',3' position of the carbocyclic ring. These compounds can be considered as analogues of carbovir and other nucleoside analogues with interesting pharmacological properties.

Racemic mixtures of compounds **6** - **8** with *cis* stereochemistry, were prepared as shown in scheme 1. The key intermediate (\pm) *cis*-2-amino-3-cyclopentenylmethanol (**4**) was synthesized in good yield from the cyclopentadiene in 4 steps: treatment of cyclopentadiene (**1**) with chlorosulfonyl isocyanate to obtain the lactame **2** corresponding to an 2+2 cycloaddition; hydrolysis of this lactame to 2-amino-3-cyclopentenecarboxylic acid; formation of the methyl ester via acid chloride; and final reduction of the resulting amino ester **3** with lithium borohydride. The purine base was then constructed about the primary amino group of these intermediates.¹ To obtain the 6-substituted purines (**6a** - **8a**), the amino alcohol **4** was reacted with 5-amino-4,6-dichloropyrimidine, which afforded **5a**, and to obtain the 2,6-disubstituted purines (**6b** - **8b**), the amino alcohol **4** was firstly reacted with 2-amino-4,6-dichloropyrimidine, and then a second amino group was introduced at position 5 of the pyrimidine ring by reaction with p-

chlorobenzenediazonium chloride followed by reduction to afford the compound **5b**. The fused imidazole ring was then formed in compound **5a** or **5b**, by reaction with ethylorthoformate in acid medium, which afforded respectively 6-chloropurine **6a** and 2-amino-6-chloropurine **6b**.

The 6-hydroxy analogues **7a** and **7b** were prepared in good yield by treatment of **6a** and **6b** respectively with NaOH and similar good yields of the 6-amino analogues **8a** and **8b** were obtained by amination of **6a** and **6b** in metanol.²



i: CSI, ether dry. ii: a) HCl 12M; b) MeOH dry, Cl₂SO; c) amberlite IRA 420(OH)ion-exchange resin. iii: LiBH₄, THF dry. iv: 5-amino-4,6-dichloropyrimidine, n-BuOH, Et₃N. v: a) 2-amino-4,6-dichloropyrimidine, n-BuOH, Et₃N; b) p-chlorophenyldiazonium chloride, AcONa.3H₂O; c) Zn, AcOH, H₂O, EtOH. vi: CH(EtO)₃, HCl 12M. vii: NaOH 0.5M. viii: MeOH, NH₄OH.

SCHEME 1

REFERENCES

1. Vince, R.; Hua, M. *J. Med. Chem.*, **1990**, 33, 17-21.
2. All compounds had spectral and analytical data consistent with their structures.